

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Clover Biopharmaceuticals, Ltd.

三葉草生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2197)

VOLUNTARY ANNOUNCEMENT INCLUSION ON THE HANG SENG COMPOSITE INDEX

This announcement is made by the board of directors (the “**Board**”) of Clover Biopharmaceuticals, Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors on the latest business development of the Group.

The Board is pleased to announce that the Company’s shares will be included as a constituent stock of the Hang Seng Composite Index (“**HSCI**”) with effect from March 7, 2022.

The HSCI offers a comprehensive Hong Kong market benchmark that covers about 95% of the total market capitalization of companies listed on the Main Board of The Stock Exchange of Hong Kong Limited. Inclusion into the HSCI will allow the Company’s stock to be eligible for trading on the Hong Kong Stock Connect, a channel for stock trading between investors in Hong Kong and those in mainland China.

The Board is of the view that the inclusion of the Company’s shares into the HSCI represents capital market’s recognition of the Company’s performance and value, which will potentially help increase the trading liquidity of shares of the Company, broaden the Company’s shareholder base and raise global awareness. All of these factors will be integral as the Company completes global regulatory filings for the Company’s COVID-19 vaccine candidate and advance the Company’s portfolio of innovative vaccine and oncology therapies.

Shareholders of the Company and potential investors are advised to exercise caution in dealing in the securities of the Company.

By order of the Board
Clover Biopharmaceuticals, Ltd.
Dr. Peng LIANG
Chairman of the Board

Chengdu, PRC, February 24, 2022

As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG, Mr. Ting XIAO and Mr. Dong LYU as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.